Hoth Therapeutics, Inc.

Informe acción NasdaqCM:HOTH

Capitalización de mercado: US$5.9m

Hoth Therapeutics Dirección

Dirección controles de criterios 3/4

Hoth Therapeutics' CEO is Robb Knie, appointed in May 2017, has a tenure of 7.5 years. total yearly compensation is $868.82K, comprised of 51.8% salary and 48.2% bonuses, including company stock and options. directly owns 0.84% of the company’s shares, worth $49.99K. The average tenure of the management team and the board of directors is 5.7 years and 4.8 years respectively.

Información clave

Robb Knie

Chief Executive Officer (CEO)

US$868.8k

Compensación total

Porcentaje del salario del CEO51.8%
Permanencia del CEO7.5yrs
Participación del CEO0.8%
Permanencia media de la dirección5.7yrs
Promedio de permanencia en la Junta Directiva4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Sep 20

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Jun 29

Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Nov 12
Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Hoth Therapeutics extends agreement for experimental antibiotic

Jun 18

We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Jun 10
We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic

May 05

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

May 03

Hoth provides pipeline and regulatory timeline update

Feb 02

FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%

Jan 13

Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer

Jan 11

Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%

Jan 04

Hoth therapeutics signs production agreement for HT-001, Shares up 75%

Dec 31

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Robb Knie en comparación con los beneficios de Hoth Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$869kUS$450k

-US$8m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$1mUS$450k

-US$11m

Sep 30 2022n/an/a

-US$11m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$400k

-US$14m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$781kUS$350k

-US$7m

Sep 30 2020n/an/a

-US$10m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019US$2mUS$350k

-US$8m

Sep 30 2019n/an/a

-US$4m

Jun 30 2019n/an/a

-US$3m

Mar 31 2019n/an/a

-US$3m

Dec 31 2018US$308kUS$250k

-US$2m

Sep 30 2018n/an/a

-US$3m

Dec 31 2017US$146kUS$146k

-US$3m

Compensación vs. Mercado: Robb's total compensation ($USD868.82K) is above average for companies of similar size in the US market ($USD655.65K).

Compensación vs. Ingresos: Robb's compensation has been consistent with company performance over the past year.


CEO

Robb Knie (55 yo)

7.5yrs

Permanencia

US$868,823

Compensación

Mr. Robb Knie is Founder of Hoth Therapeutics, Inc. Mr. Knie served as the Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors of FoxWayne Enterprises Acquisition Corp....


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Robb Knie
Founder7.5yrsUS$868.82k0.84%
$ 50.0k
David Briones
Chief Financial Officer5.7yrssin datossin datos
Hayley Springer
Executive Vice President of Operations2.5yrssin datossin datos

5.7yrs

Permanencia media

Equipo directivo experimentado: HOTH's management team is seasoned and experienced (5.7 years average tenure).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Robb Knie
Founder7.5yrsUS$868.82k0.84%
$ 50.0k
Adam Friedman
Member of Scientific Advisory Board7.3yrssin datossin datos
Mario Lacouture
Member of Scientific Advisory Board3.8yrssin datossin datos
David Sarnoff
Independent Director6.3yrsUS$65.21k0.014%
$ 859.7
William Weglicki
Member of Scientific Advisory Board4.9yrssin datossin datos
Wayne Linsley
Independent Director4.6yrsUS$65.21k0.0019%
$ 115.2
Glenn Cruse
Member of Scientific Advisory Board4.8yrssin datossin datos
Graig Springer
Independent Director4.8yrsUS$65.21k0.018%
$ 1.1k
Sergio Traversa
Member of Scientific Advisory Boardno datasin datossin datos
Jeff Pavell
Independent Director1.9yrsUS$65.21k0.074%
$ 4.4k
John Cirrito
Member of Scientific Advisory Board2.8yrssin datossin datos
Carla Yuede
Member of Scientific Advisory Board2.8yrssin datossin datos

4.8yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: HOTH's board of directors are considered experienced (4.8 years average tenure).